Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews

Katrina M. Romagnoli, Scott D. Nelson, Lisa Hines, Philip Empey, Richard D. Boyce and Harry Hochheiser

Abstract

Background: Drug information compendia and drug-drug interaction information databases are critical resources for clinicians and pharmacists working to avoid adverse events due to exposure to potential drug-drug interactions (PDDIs). Our goal is to develop information models, annotated data, and search tools that will facilitate the interpretation of PDDI information. To better understand the information needs and work practices of specialists who search and synthesize PDDI evidence for drug information resources, we conducted an inquiry that combined a thematic analysis of published literature with unstructured interviews.

Methods: Starting from an initial set of relevant articles, we developed search terms and conducted a literature search. Two reviewers conducted a thematic analysis of included articles. Unstructured interviews with drug information experts were conducted and similarly coded. Information needs, work processes, and indicators of potential strengths and weaknesses of information systems were identified.

Results: Review of 92 papers and 10 interviews identified 56 categories of information needs related to the interpretation of PDDI information including drug and interaction information; study design; evidence including clinical details, quality and content of reports, and consequences; and potential recommendations. We also identified strengths/weaknesses of PDDI information systems.

Conclusions: We identified the kinds of information that might be most effective for summarizing PDDIs. The drug information experts we interviewed had differing goals, suggesting a need for detailed information models and flexible presentations. Several information needs not discussed in previous work were identified, including temporal overlaps in drug administration, biological plausibility of interactions, and assessment of the quality and content of reports. Richly structured depictions of PDDI information may help drug information experts more effectively interpret data and develop recommendations. Effective information models and system designs will be needed to maximize the utility of this information.

Keywords: Decision support systems, Clinical, Drug interactions, Drug information services, Information needs, Clinical recommendations

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
A potential drug-drug interaction (PDDI) occurs when a patient is exposed to two or more drugs that are known to interact. Robust and accurate information regarding the potential adverse impacts of co-administration of drugs is critical for reducing the health impacts and costs of adverse events. The importance of this information is demonstrated by the existence of numerous print and online resources that summarize PDDI information, including institutional prescribing guidelines. Unfortunately, these resources also illustrate the challenges faced in interpreting PDDI information. An analysis of 14 publicly available resources identified wide variation in content, with the overlap between interacting drug pairs between any two sources at generally less than 50% [1]. Several studies have found similarly substantial disagreement in the content of commercial sources of PDDI information [2–4].

The disagreements between resources that provide PDDI information are likely the result of the complexity of the task and the variability of the goals. Relevant details are distributed across multiple sources, including published literature, regulatory documents, drug labels, and case reports, each of which must be evaluated for credibility on its own merits and with respect to other, potentially conflicting, reports. Differences in goals may also account for discrepancies. One reviewer aiming to comprehensively identify all PDDIs may include information that might be ignored by a different reviewer who is interested only in likely, serious, and actionable interactions. Although some standardized practices for evaluating PDDI information have been developed [5, 6], concerns about the potential negative impact of methodological variations have led to calls for increased rigor [3].

Our broader goal – and the specific focus of this paper – is to develop information models and tools that will provide drug-drug interaction experts with clear and usable views of structured PDDI evidence, thus facilitating interpretation and hopefully increasing the quality and utility of PDDI information that reaches clinicians and patients. We are currently developing a semantic model of PDDI evidence suitable for creating structured descriptions of relevant reports, results, attribution of claims, and similar details necessary for assessing the clinical implications of PDDI descriptions [1, 7–10]. To populate these models, we are also developing annotation tools suitable for extracting these details from case reports, clinical trials, regulatory documents, product labels, and tertiary literature [11, 12]. A pilot study of the feasibility of engaging non-expert users to conduct such annotations suggests that these tools might be useful for crowd-sourcing the extraction of relevant PDDI information [13].

Although useful for bringing needed structure to PDDI information, these models and tools will not be accepted by users if they do not appropriately meet important information needs and support well-established practices. The work of reviewing and interpreting PDDI evidence is conducted by a relatively small and understudied group of drug information specialists with advanced PDDI knowledge. Here, we examine prior literature and interview responses from these experts to develop information needs and workflow models suitable for informing the design of informatics tools in support of PDDI information interpretation. The combination of data models, annotation tools, and an inexpensive approach to annotation presents the possibility of normalizing PDDI information on a large scale, turning complex unstructured textual reports into structured knowledge bases suitable for interrogation by experts involved in creation of compendia, guidelines, and similar resources. These tools will also be of interest to regulatory agencies responsible for providing guidance to industry regarding reporting of PDDI information [14–17].

Objective
To identify factors influencing the interpretation and use of information necessary for making clinical recommendations about PDDIs, and to use the experience of practitioners to provide context for these factors. The key questions are:

1. What knowledge and factors influence drug decision making regarding PDDIs?
2. What is the workflow for seeking and synthesizing PDDI information during tasks such as clinical consultations for medication therapy decisions and guideline development?
3. What barriers do drug information experts report as obstacles to satisfying their information needs during PDDI information synthesis?

Methods
Overview
We conducted a literature search of the knowledge and factors that influence medication decision-making regarding PDDIs and workflows for seeking and synthesizing PDDI information; structured interviews with four potential users of an evidence assessment tool; and unstructured interviews with six drug information experts. Papers from the literature and interview transcripts were used to generate lists of information needs and a workflow model describing the process of reviewing PDDI information.
Literature search

Two PharmD pharmacists (LH and PE) and a biomedical informatician (RDB), each with extensive knowledge of drug information and drug interactions, suggested potentially relevant articles based on their knowledge and experience. Of the articles discussed by the group, seventeen (Additional file 1: Appendix A) were selected as “seed” articles for developing a search strategy. MeSH terms and other keywords from these papers were used to develop MEDLINE and EMBASE queries (Additional file 1: Appendix B). After removing duplicates, two authors (KMR and RDB) independently screened the identified titles and abstracts to verify relevance to the project objectives (above). Disagreements were resolved by discussion.

These papers were then screened for inclusion/exclusion using criteria focused on information needs for synthesis and evaluation of PDDI information, as opposed to resources dealing with PDDIs from the perspective of epidemiology or clinical pharmacology (Additional file 1: Appendix C). Automated methods for extracting PDDI information, such as through natural language processing were excluded. Regulatory guidelines describing requirements for discussion of drug-drug interaction information in drug labels were also excluded, as these documents act as specifications for product labeling and are not focused on information needs [14–17]. Papers citing and cited by the included papers were identified and subjected to a full-text review based on a broader set of inclusion/exclusion criteria by two of the authors (KMR and HH), resulting in a final set of papers for review. A summary of the search workflow can be found in Fig. 1.

Two authors (KMR and SN) conducted an open-coding qualitative analysis of the included articles to create a hierarchical coding scheme [18, 19] identifying information needs and factors relevant to making clinical recommendations about PDDIs. Initial categories for coding were derived from the study objectives described above, from Friedman & Wyatt’s nine types of evaluation...
Expert interviews
We conducted unstructured interviews with six experts involved in the synthesis of PDDI information. Participants included clinical pharmacists, drug information compendia editors, and academic drug information specialists who had previously participated in a conference series focusing on improving PDDI information [3]. Questions addressed respondents’ workflows, information needs, and information synthesis processes when conducting clinical consultations on drug-drug interactions and guideline development. When possible, respondents were asked to illustrate key aspects of their workflows and interpretive practices. Interviews were conducted by phone and web conference, during which the conversations were recorded via audio recording and screen capture of participants’ computers, when possible. We also reviewed transcripts of four interviews discussing a tool to help standardize the assessment of evidence for the existence of a drug-drug interaction [3]. All interviews were approved as exempt by the University of Pittsburgh Institutional Review Board.

Interview recordings were transcribed verbatim. As one interview was not recorded due to technical difficulties, interviewer notes were used in place of recording transcripts. Texts were coded using the same codebook used for the analysis of the literature search, with new codes added as needed to code concepts not found in the literature review. Graphical workflow models were developed to illustrate participants’ workflows, information seeking behavior, criteria for evaluating information, decision-making criteria, and other relevant aspects of the process of synthesizing PDDI information.

Model generation
Codes from the literature search were reviewed to extract categories of information needs and specific types of information representing each of the categories. Information needs identified through analysis of expert interviews and through the construction of graphical workflows were added to the categories identified from the literature search, through a consensus process involving two of the authors (KMR and HH). These needs were added to the qualitative codebook and interviews were recoded to account for these new codes. The resulting codes were reviewed by two authors (KMR and HH) to identify recurring information needs. Individual workflows were condensed into a consensus model, informed by Goldschmidt’s model of information synthesis [21].

Results

Literature review and interview informants
Our original set of 17 articles (Additional file 1: Appendix A) led to another 36 articles identified during the database search. Reference searches for these articles led to the identification of an additional 39 articles. After de-duplication and the inclusion of seven additional gray-literature articles identified by the authors, the final set included 92 sources (Fig. 1) which were coded along with the four interviews regarding the proposed PDDI evidence assessment instrument and six interviews with compendia editors [3]. The full list of papers analyzed is available in Additional file 1: Appendix D. A subset of slightly over 20% of the papers (22 out of 92, 23.9%) was double-coded.

Inter-rater reliability of the final coding was substantial (poled kappa = 0.66).

PDDI information needs
Analysis of the literature review and interviews led to the identification of 56 primary information needs, summarized and classified into four categories (Table 1, full details including links to specific literature references and identification of needs identified in interviews given in Additional file 1: Appendix D). Drug and interaction information includes basic information known about the drugs involved in any study and their hypothetical roles in potential drug-drug interactions. Study design information needs reflect the criteria used by experts to assess the scientific applicability and validity of clinical and experimental studies, addressing issues such as experimental design, characteristics of participants, and relevance of doses. Examples of pertinent patient characteristics included clinical profiles of the participants, as healthy individuals might not be appropriate proxies for individuals experiencing symptoms treated by the medication. Similarly, studies involving dosages larger than typically prescribed might be...
considered uninformative. Evidence information needs were further divided into three subcategories: quality and content of report describing aspects of result reporting that might impact validity judgments, clinical factors describing the context of the interactions, and consequences enumerating possible adverse outcomes. Recommendations, the final category of information need, describes clinical actions that might be used to avoid potentially adverse effects.

**Expert interviews**

Discussions with PDDI information experts suggested a range of personalized and informal practices. PDDI information review generally began either with a request for information from colleagues or clients, or from new papers or reports describing potential interactions. Informants relied on a variety of resources to identify relevant information, including PubMed (the most frequently mentioned resource), Google searches, Medwatch event reports, existing compendia, and new drug announcements. Although one respondent indicated that direct inquiries to manufacturers were occasionally useful, there was little enthusiasm across all respondents for the use of product labels.

Interviewees discussed a number of heuristics for evaluating both trials and case reports. Patient characteristics, dosages of potentially interacting drugs, temporal overlap of the drugs, and general plausibility of the PDDI were among the characteristics used to evaluate the relevance and importance of both clinical trials and case reports. Respondents discussed the use of specific criteria for evaluating both the design and the reporting of randomized controlled trials, describing the use of appropriate sample size calculations, controls, and participants and detailed reporting of specific effect sizes and statistical reports (area under the curve changes, p-values, confidence values) as indicative of high-quality design. There was a clear agreement that descriptions of theoretically-possible interactions were much less compelling than observed interactions. Along these lines, one respondent, who focused on Food and Drug Administration new drug announcements, discussed placing higher weight on reports involving human data, as opposed to results only observed in animal studies.

Respondents used a combination of heuristic and subjective processes to synthesize interpretations, attempting to derive conclusions from multiple, potentially conflicting reports. Considerations of the likely impact

---

**Table 1** Information needs for interpreting potential drug-drug interaction reports, with indications of sources identifying those needs (literature and/or interviews) and counts of the number of sources mentioning each need

| Category                        | Source               | Subcategory                        | Information needs                                                                 |
|---------------------------------|----------------------|------------------------------------|-----------------------------------------------------------------------------------|
| Drug and Interaction Information| Literature and Interviews | Quality and content of report | Mechanisms of action (45 sources); pharmacokinetics (34); temporal overlap in administration of interacting drugs (27); pharmacodynamics (22); frequency of co-administration (16); category (drug class/related drugs) (14); biological plausibility of interaction (14); interaction role (object/precipitant) (4); |
| Study Design (randomly controlled trials) | Interviews | Dosage (5); participant characteristics (4); number of participants (3); controls (2); sample size calculation (1); |
| Evidence                        | Literature and Interviews | Quality and content of report | Drug Interaction Probability Scale [38] scores (10); differentiation between statistical and clinical significance (3); statistical characterization of results (3); inclusion of result magnitude (3); lack of evidence of interactions (2); thoroughness of new drug application (1); inclusion of human (non-animal) data as more credible (1); omissions of important details (1); Number of cases (1) |
| Patient Factors                 | Clinical status (50); demographics (28); medication history (10); allergies (7); body weight (7); lifestyle (6); compliance (4); inter-patient variability (4); number of prescribers/pharmacies (2); length of hospital stay (1); payer status (1) |
| Clinical                        | Dose (28); risk factors for consequences (21); clinical context (15); mitigating factors (11); |
| Seriousness                     | Clinical importance (25); likelihood of irreversible morbidity (17); likelihood of mortality (14); likelihood of prescriber action (2) |
| Adverse effects                 | Frequency of adverse events (numeric and/or estimated) (10); toxicity (6); reversibility of adverse effects (2); alteration of therapeutic effect (2); |
| Recommendations                 | Monitor (33); dose adjustment (25); change medication (20); contraindication (20); discontinue or temporarily hold medication (13); modify administration (11); patient education (10); alternative therapy (10); strength of recommendation (9); continue treatment (7); when to start/stop management (2); seek medical attention (1); cost-effectiveness of recommendation (1) |
of the interaction, in terms of prevalence and seriousness, were frequently cited, with some respondents indicating that a single, sufficiently serious report might be sufficient to reach the conclusion that a PDDI was serious enough to merit concern. Although interviewees shared an interest in using sound science and considering all of the available information, differences in intended uses of recommendations led to different preferences in terms of tradeoffs between false positives and false negatives. Specifically, one respondent who edited a drug information compendium indicated a desire to be comprehensive, including all interactions supported by high levels of credible evidence, while another interviewee who made recommendations for drug alerting systems was much more concerned about the potential negative implications of false positives, instead preferring only interactions with high likelihoods of serious consequences.

The PDDI review processes described by the interviewees were personal and informal. Most reviews started with online searches for literature (primarily through PubMed) and other resources. Evaluation of results, selection of resources, and interpretations was conducted informally, with no dedicated support from information tools such as reference management software or databases. Although some interviewees described filing of papers (either electronic copies or printed copies), no respondents mentioned any systematic effort to track which sources were reviewed in the course of evaluating any particular PDDI. One interviewee indicated that it was easier to conduct searches from scratch than to take the time to catalog which sources had been reviewed. The determination of when sufficient information had been gathered to make a recommendation was described as generally heuristic and subjective, focused on gathering sufficient data for a recommendation, as opposed to systematic investigation of all available evidence. Contents of recommendations included free text; structured reports providing recommendations on a scale of severity ranging from “no interaction” to “never prescribe together”; and summaries using structured templates described in the literature [6]. A graphical summary of the PDDI evidence evaluation workflow is given in Fig. 2.

**Discussion**

Our review of 92 papers and interviews with ten domain experts provides a preliminary catalog of the types of information that are needed to interpret the importance of a PDDI. Although basic information on the drugs involved and the nature of the potential interaction are obvious starting points, more detail is needed to interpret the clinical importance of a PDDI. Contextual information, such as patient-specific risk factors and the likelihood of occurrence of a serious adverse event, is critical to guide useful recommendations. The quality, strength, relevance, and source of...
the evidence about an interaction matter as well: evidence from large clinical trials involving patients may be given more credence than in vitro experiments or data from animal studies.

Although many similar themes were identified both in the reviewed literature and in our interviews, the latter provided valuable insight into the process of interpreting evidence for PDDIs (Fig. 2). Experts described personalized and heuristic evidence review processes designed to assess the validity of the study design and the reported results. For example, reports of specific numeric magnitudes of effect sizes were described as being more trustworthy and convincing than comparable reports describing effects in qualitative terms (e.g. as “substantial increase”). Resulting reports or recommendations were also fairly subjective in content, although one respondent did discuss using a structured template to describe results [6].

Reducing the substantial impact of adverse events caused by drug-drug interactions is in many ways an information challenge. Clear, accurate, and useful PDDI information can help clinicians choose medication regimens that reduce the risk of adverse events. Although drug information specialists work diligently to interpret and synthesize relevant information for use by clinicians, the conversion of available evidence into guidance is a cognitively complex process, involving the extraction of information from research publications, event reports, product labels, and other free-text sources; the evaluation of the relevance and credibility of that information; and the construction of informative summaries. The difficulties inherent in these processes are reflected in differences in coverage and content across various drug interaction knowledge bases, whether or not they were developed for commercial purposes [1, 24–26]. Several research efforts have attempted to tackle the challenge of extracting and representing PDDI information through techniques including natural language processing and crowdsourcing [13, 27–32]. However, much less attention has been paid to the processes of evaluating this information and synthesizing evidence.

Concern over the quality of PDDI information is not a new finding from this study. Our results are consistent with findings from recent examinations of drug-drug interaction resources and information models. Our literature review and interviews identified all of the data elements identified in our earlier survey of 14 publicly available drug-drug interaction information resources [1]. More recently, Herrero-Zazo, et al. examined 15 conceptual models of drug-drug interactions, identifying a set of 19 concepts [33]. Although categorizations and terms differ, information needs identified in our survey include all of these 19 concepts. Our results in this paper included several elements not found in either of these earlier efforts, including temporal overlaps in drug administration, biological plausibility of interactions, and assessments of the quality and content of the reports.

In response to concerns over PDDI information quality, a workgroup convened in early 2013 developed a consensus set of recommendations for evaluation of PDDI evidence, including the development of DRIVE: the Drug Interaction eVidence Evaluation instrument [3]. Although the recommendations of the workgroup are generally consistent with the information needs identified in our study, gaps between the workflows discussed during our interviews and the systematic evaluation proposed by the workgroup are substantial. Our expert interviews clearly suggest that the process of synthesizing PDDI information is idiosyncratic and highly personalized, with individuals differing on approaches to information seeking and interpretation, as well as the importance they ascribed to different aspects of the information. The development of software tools for managing the PDDI evidence synthesis workflow as a systematic process (as intended by DRIVE), while also supporting significant variations in information management, is an important product subject of future research.

Our findings also offer some suggestions to regulatory agencies responsible for providing guidance on PDDI content in drug product labels. Consistent with our results, current US Food and Drug Abbreviation guidelines suggest the inclusion of recommendations for dose adjustments, discussion of mechanisms of interaction, details of changes in concentrations of drugs or metabolites, and description of the source of the results. US guidelines also suggest the inclusion of any interference with lab tests [14], a factor not identified in our study. The inclusion of details identified in our study, including discussion of specifics of relevant patient factors; temporal factors; study designs and related reports; and adverse event seriousness might make the PDDI content in drug labels more useful both for drug information specialists and for practicing clinicians. Several of these elements, including temporal factors and related recommendations; clear recommendations; details specific to subpopulations; and variability of the response are discussed in European labeling guidelines [16]. Information needs might also play a role in considerations about the format of drug product labels. As currently specified in US guidelines, PDDI information might be found in distributed across multiple label sections including one dedicated to drug interactions [14]. Consolidation of all of these details into the drug interactions section, as opposed to cross-referencing those other sections, might increase the utility of these labels.

**Limitations**

There were two limitations to our literature review. First, as the search terms were identified based on the seed list
of 17 papers, biases in this list may have influenced our searches and the resulting list of papers considered for inclusion. Second, as our literature review did not include a systematic search of gray literature or non-English publications, our synthesis of factors identified in the literature may be incomplete. Other potential limitations include the small number of interviews: inclusion of additional experts may have led to the identification of additional factors or processes, along with potentially clearer insight into the prevalence and importance of information needs and related factors. As most of the discussion in the interviews involved descriptions of workflows, rather than demonstration of work in context, interview contents and analysis may suffer from problems of recall and decontextualization. Additional interviews involving observation of DDI evidence review in situ might provide additional insights [19, 34]. Although our analytic processes, including coding by multiple reviewers and consensus revisions to codebooks, should increase the generalizability of our interpretations, standard risks of biases of qualitative research apply.

**Conclusion**

Improvements in the quality and utility of clinically-relevant descriptions of PDDIs have the potential to contribute to reductions in both adverse events and, through clinical decision support systems, related costs [35]. Identifying relevant PDDI information research literature and other sources is highly complex. As this process will require manual curation for the foreseeable future [13], greater understanding of the information needs associated with PDDI information synthesis will be necessary to inform the design and content of tools designed to help drug information specialists conduct systematic and rigorous reviews. Our thematic analysis of the literature and interviews with experts provide a detailed view of the breadth and depth of necessary information, and the workflows associated with the processes. These insights will inform our ongoing efforts to develop richer information models for structured representation of drug-drug interaction evidence [1, 8, 9, 36]. The combination of these enhanced models with improvements to the usability of drug-drug interaction decision support presents the possibility for significant improvements in drug safety [37].

**References**

1. Ayvaz S, Hom J, Hassanzadeh O, Zhu Q, Stan J, Tatonetti NP, Vilar S, Brochhausen M, Samwald M, Rastegar-Mojarad M, et al. Toward a complete dataset of drug-drug interaction information from publicly available sources. J Biomed Inform. 2015;55:206–21.
2. Saverno KR, Hines LE, Warholak TL, Grizzle AJ, Babits L, Clark C, Taylor AM, Malone DC. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. J Am Med Inform Assoc. 2011;18:32–7.
3. Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, Abernethy DR, Horn JR, Sklar SJ, Wong SK, et al. Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf. 2015;38:197–206.
4. Wang LM, Wong M, Lightho姆 JM, Cheng CM. Black box warning contraindicated comediations: concordance among three major drug interaction screening programs. Ann Pharmacother. 2010;44:28–34.
5. Böttiger Y, Laine K, Andersson ML, Oxęjo M-I, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B, Korhonen T, Molin B. SFIND-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65(6):627–33.

6. Van Roon EN, Fikwee S, Le Comte M, Langendijk PNJ, Kwee-Zuidervijk WJM, Smits P, Brouwer JRB. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf. 2005;28(11):131–9.

7. Brochhausen M, Schneider J, Malone D, Empey PE, Hogan WR, Boyce RD. Towards a foundational representation of potential drug-drug interaction knowledge. In: The 1st International Drug-Drug Interaction Knowledge Representation Workshop (DINR 2014) Collocated with the 2014 International Conference on Biomedical Ontology (ICBO 2014). Houston: CEUR-WS; 2014. p. 16–31. BT - CEUR Workshop Proceedings.

8. Schneider J, Brochhausen M, Rosko S, Ciccarese P, Hogan WR, Malone D, Ning Y, Clark T, Boyce RD. Formalizing knowledge and evidence about potential drug-drug interactions. In: The International Workshop on Biomedical Data Mining, Modeling, and Semantic Integration: A Promising Approach to Solving Unmet Medical Needs (BDM21) 2015 at the 14th International Semantic Web Conference (ISWC). October 11, 2015; 2015; Bethlehem, PA; 2015.

9. Schneider J, Ciccarese P, Clark T, Boyce RD. Using the Micropublications ontology and the Open Annotation Data Model to represent evidence within a drug-drug interaction knowledge base. In: The 4th Workshop on Linked Science 2014—Making Sense Out of Data (USC4L2014) Collocated with the 13th International Semantic Web Conference (ISWC2014). Trentino, Italy; 2014.

10. The Potential Drug-Drug Interaction and Potential Drug-drug Interaction Evidence Ontology (DIDEO). https://github.com/DIDEO/DIDEO. Accessed 19 Feb 2017.

11. AnnotatorPress. https://dkib.org/dbmi-annotator/. Accessed 19 Feb 2017.

12. Github repository for AnnotatorPress. https://github.com/dbmipi/dbmi-annotator. Accessed 19 Feb 2017.

13. Hochheiser H, Ning Y, Hernandez A, Horn JR, Jacobson R, Boyce RD. Using None Expert annotator for Annotating Pharmacokinetic Drug-Drug Interaction Mentions in Product Labeling: A Feasibility Study. JWIR Res Protoc. 2016;5(2):e40. doi:10.2196/resprot.5028. PMID: 27066806. PMCID: 4849909.

14. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry drug interaction studies — study design, data analysis, implications for dosing, and labeling recommendations. 2012.

15. Drug Interactions and Labeling - Drug Development and Drug Interactions: Regulatory Guidance and Manual for Policies and Procedures. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093606.htm. Accessed 19 Feb 2017.

16. Guideline on the investigation of drug interactions. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf. Accessed 19 Feb 2017.

17. Yeung CK, Yoshida K, Kusama M, Zhang H, Ragueneau-Majlessi I, Argon S, Li N, Chang P, Le CD, Zhao P, et al. Organ impairment—drug–drug interaction database: a tool for evaluating the impact of renal or hepatic impairment and pharmacologic inhibition on the systemic exposure of drugs. CPT: Pharmacometrics Syst Pharmacol. 2015;4(8):489–94.

18. Corbin J, Strauss AL. Basics of qualitative research. 4th ed. Los Angeles: Sage Publications; 2014.

19. Lazar J, Feng JH, Hochheiser H. Research methods in human-computer interaction. 2010.

20. Friedman CP, Wyatt J. Evaluation methods in biomedical informatics. 2006.

21. Goldschmidt PG. Information synthesis: a practical guide. Health Serv Res. 1986;21:215–37.

22. Halgren KA. Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol. 2012;8:23–34.

23. De Vries H, Elliott MN, Kanouse DE, Teleki SS. Using pooled kappa to summarize interrater agreement across many items. Field Methods. 2006;18:272–82.

24. Eksten D, Tirosh M, Eyal Y, Eyal S. Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels. Epilepsy Behav. 2015;44:218–24.

25. Ribacia J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc. 2004;44:136–41.

26. Olvey EL, Clauschee S, Malone DC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther. 2010;87:48–51.

27. Boyce R, Gardner G, Harkema H. Using natural language processing to Extract Drug-Drug Interaction Information from Package Inserts. In: 2012 Workshop on BioNLP. 2012; Montreal, Quebec: Association for Computational Linguistics; 2012. p. 206–13.

28. Bui Q-C, Sloot PMA, van Mulligen EM, Kors JA. A novel feature-based approach to extract drug-drug interactions from biomedical text. Bioinformatics (Oxford, England). 2014;30:3365–71.

29. Kim S, Liu H, Yeganova L, Wilbur JW. Extracting drug-drug interactions from literature using a rich feature-based linear kernel approach. J Biomed Inform. 2015;55:23–30.

30. Liu S, Tang B, Chen Q, Wang X. Drug-drug interaction extraction via convolutional neural networks. Comput Math Methods Med. 2015;2016:6918381.

31. Segura-Bedmar I, Martinez P, de Pablo-Sánchez C. Using a shallow linguistic kernel for drug-drug interaction extraction. J Biomed Inform. 2011;44:789–804.

32. Zhang Y, Lin H, Yang Z, Wang J, Li Y. A single kernel-based approach to extract drug-drug interactions from biomedical literature. PLoS One. 2012;7:e48901.

33. Herrero-Zazo M, Segura-Bedmar I, Martinez P. Conceptual models of drug-drug interactions: a summary of recent efforts. Knowledge-Based Systems. 2016;114:999–107.

34. Beyer H, Holtzblatt K. Contextual design: defining customer-centered systems. 1998.

35. Helmers PJ, Suijkerbuijk BO, Nannan Panday PV, Kosterink JGW. Drug-drug interaction checking assisted by clinical decision support: a return on investment analysis. J Am Med Inform Assoc. 2015;22:764–72.

36. Boyce RD, Horn JR, Hassanzadeh O, Waard A, Schneider J, Luciano JS, Rastegar-Mojarrad M, Liakata M. Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness. J Biomed Semant. 2013(4)(15).

37. Payne TH, Hines LE, Chan RC, Hartman S, Kapusnik-Unner J, Russ AL, Chaffee BW, Hartman C, Tamis V, Galbreth B, et al. Recommendations to improve the usability of drug-drug interaction clinical decision support alerts. J Am Med Inform Assoc. 2015;22:1243–50.

38. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674–80.